Advertisement

Getting to Zero: Targeting Psychiatric Comorbidities as Drivers of the HIV/AIDS Epidemic

  • Adam W. CarricoEmail author
Commentary

Since the early days of the HIV/AIDS epidemic, psychiatric comorbidities such as mental health and substance use disorders have been linked to greater risk for HIV seroconversion [1], onward HIV transmission [2], and clinical HIV progression [3, 4]. In recent years, groundbreaking advances in biomedical prevention have demonstrated that we have the tools to end the HIV/AIDS epidemic. Early initiation of anti-retroviral therapy by HIV-positive persons, commonly referred to as HIV treatment as prevention (TasP), optimizes health outcomes and dramatically reduces onward HIV transmission rates [5, 6]. Among HIV-negative persons, pre-exposure prophylaxis (PrEP) substantially decreases risk for HIV seroconversion [7]. Realizing the clinical and public health benefits of these advances will require expanded efforts to address prevalent psychiatric comorbidities that undermine the effectiveness of biomedical approaches to HIV/AIDS prevention. This issue of the International Journal of...

Notes

Compliance with Ethical Standards

Conflict of Interest

The author declares that there is no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any the author.

Informed Consent

There were no human subjects in this submission.

References

  1. 1.
    Mimiaga MJ, O'Cleirigh C, Biello KB, et al. The effect of psychosocial syndemic production on 4-year HIV incidence and risk behavior in a large cohort of sexually active men who have sex with men. J Acquir Immune Defic Syndr. 2015;68(3):329–36.  https://doi.org/10.1097/QAI.0000000000000475.CrossRefGoogle Scholar
  2. 2.
    Sikkema KJ, Watt MH, Drabkin AS, Meade CS, Hansen NB, Pence BW. Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model. AIDS Behav. 2010;14(2):252–62.  https://doi.org/10.1007/s10461-009-9650-y.CrossRefGoogle Scholar
  3. 3.
    Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med. 2008;70(5):539–45.  https://doi.org/10.1097/PSY.0b013e3181777a5f.CrossRefGoogle Scholar
  4. 4.
    Carrico AW. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci. 2011;88(21–22):940–7.  https://doi.org/10.1016/j.lfs.2010.10.002.CrossRefGoogle Scholar
  5. 5.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830–9.  https://doi.org/10.1056/NEJMoa1600693.CrossRefGoogle Scholar
  6. 6.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.  https://doi.org/10.1056/NEJMoa1105243.CrossRefGoogle Scholar
  7. 7.
    Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.  https://doi.org/10.1097/QAD.0000000000001145.CrossRefGoogle Scholar
  8. 8.
    Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRefGoogle Scholar
  9. 9.
    Keiser O, Spoerri A, Brinkhof MW, Hasse B, Gayet-Ageron A, Tissot F, et al. Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. Am J Psychiatry. 2010;167(2):143–50.  https://doi.org/10.1176/appi.ajp.2009.09050651.CrossRefGoogle Scholar
  10. 10.
    Shim EJ, Lee SH, Kim NJ, et al. Suicide risk in persons with HIV/AIDS in South Korea: a partial test of the interpersonal theory of suicide. Int J Behav Med. 2019.Google Scholar
  11. 11.
    Folkman S, Moskowitz JT. Positive affect and the other side of coping. Am Psychol. 2000;55(6):647–54.CrossRefGoogle Scholar
  12. 12.
    Rzeszutek M, Gruszczyńska E. Positive and negative affect change among people living with HIV: a one-year prospective study. Int J Behav Med 2019.Google Scholar
  13. 13.
    Carrico AW, Gomez W, Jain J, et al. Randomized controlled trial of a positive affect intervention for methamphetamine users. Drug Alcohol Depend. 2018;192:8–15.  https://doi.org/10.1016/j.drugalcdep.2018.07.029.CrossRefGoogle Scholar
  14. 14.
    Moskowitz JT, Carrico AW, Duncan LG, Cohn MA, Cheung EO, Batchelder A, et al. Randomized controlled trial of a positive affect intervention for people newly diagnosed with HIV. J Consult Clin Psychol. 2017;85(5):409–23.  https://doi.org/10.1037/ccp0000188.CrossRefGoogle Scholar
  15. 15.
    Rogers BG, Mendez NA, Mimiaga MJ, et al. “I wasn’t in my right mind”: qualitative findings on the impact of alcohol on condom use in patients living with HIV/AIDS in Brazil, Thailand, and Zambia (HPTN 063). Int J Behav Med 2019.Google Scholar
  16. 16.
    Noroozi M, Noroozi A, Sharif H, et al. Needle and syringe programs and HIV-related risk behaviors among men who inject drugs: a multilevel analysis of two cities in Iran. Int J Behav Med 2019.Google Scholar

Copyright information

© International Society of Behavioral Medicine 2019

Authors and Affiliations

  1. 1.Department of Public Health SciencesUniversity of MiamiMiamiUSA

Personalised recommendations